Literature DB >> 29330123

A bibliometric review of drug repurposing.

Nancy C Baker1, Sean Ekins2, Antony J Williams3, Alexander Tropsha4.   

Abstract

We have conducted a bibliometric review of drug repurposing by scanning >25 million papers in PubMed and using text-mining methods to gather, count and analyze chemical-disease therapeutic relationships. We find that >60% of the ∼35,000 drugs or drug candidates identified in our study have been tried in more than one disease, including 189 drugs that have been tried in >300 diseases each. Whereas in the majority of cases these drugs were applied in therapeutic areas close to their original use, there have been striking, and perhaps instructive, successful attempts of drug repurposing for unexpected, novel therapeutic areas.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29330123      PMCID: PMC5963941          DOI: 10.1016/j.drudis.2018.01.018

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  59 in total

1.  [Treatment of minor chorea with chlorpromazine].

Authors:  E B FORTES
Journal:  Port Med       Date:  1957 Aug-Sep

2.  Chlorpromazine in normal labor.

Authors:  W B HARER
Journal:  Obstet Gynecol       Date:  1956-07       Impact factor: 7.661

Review 3.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

4.  Neurosyphilis, malaria, and the discovery of antipsychotic agents.

Authors:  Frances R Frankenburg; Ross J Baldessarini
Journal:  Harv Rev Psychiatry       Date:  2008       Impact factor: 3.732

Review 5.  Exploiting drug-disease relationships for computational drug repositioning.

Authors:  Joel T Dudley; Tarangini Deshpande; Atul J Butte
Journal:  Brief Bioinform       Date:  2011-06-20       Impact factor: 11.622

Review 6.  Literature mining, ontologies and information visualization for drug repurposing.

Authors:  Christos Andronis; Anuj Sharma; Vassilis Virvilis; Spyros Deftereos; Aris Persidis
Journal:  Brief Bioinform       Date:  2011-06-28       Impact factor: 11.622

7.  The inflammation theory of disease. The growing realization that chronic inflammation is crucial in many diseases opens new avenues for treatment.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2012-10-09       Impact factor: 8.807

8.  A novel TRPV1 receptor antagonist JNJ-17203212 attenuates colonic hypersensitivity in rats.

Authors:  B J Wiskur; K Tyler; K Campbell-Dittmeyer; S R Chaplan; A D Wickenden; B Greenwood-Van Meerveld
Journal:  Methods Find Exp Clin Pharmacol       Date:  2010-10

9.  Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107.

Authors:  N Hagihara; S Walbridge; A W Olson; E H Oldfield; R J Youle
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

10.  Steroid-dependent sensorineural hearing loss in a patient with Charcot-Marie-Tooth disease showing auditory neuropathy.

Authors:  Yukihide Maeda; Yuko Kataoka; Akiko Sugaya; Shin Kariya; Katsuhiro Kobayashi; Kazunori Nishizaki
Journal:  Auris Nasus Larynx       Date:  2014-11-28       Impact factor: 1.863

View more
  51 in total

1.  Repurposing the Dihydropyridine Calcium Channel Inhibitor Nicardipine as a Nav1.8 Inhibitor In Vivo for Pitt Hopkins Syndrome.

Authors:  Sean Ekins; Ana C Puhl; Audrey Davidow
Journal:  Pharm Res       Date:  2020-06-11       Impact factor: 4.200

Review 2.  Insights into Computational Drug Repurposing for Neurodegenerative Disease.

Authors:  Manish D Paranjpe; Alice Taubes; Marina Sirota
Journal:  Trends Pharmacol Sci       Date:  2019-07-17       Impact factor: 14.819

3.  Combining Nelfinavir With Chloroquine Inhibits In Vivo Growth of Human Lung Cancer Xenograft Tumors.

Authors:  Jaclyn Lopiccolo; Shigeru Kawabata; Joell J Gills; Phillip A Dennis
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

4.  A Machine Learning Strategy for Drug Discovery Identifies Anti-Schistosomal Small Molecules.

Authors:  Kimberley M Zorn; Shengxi Sun; Cecelia L McConnon; Kelley Ma; Eric K Chen; Daniel H Foil; Thomas R Lane; Lawrence J Liu; Nelly El-Sakkary; Danielle E Skinner; Sean Ekins; Conor R Caffrey
Journal:  ACS Infect Dis       Date:  2021-01-12       Impact factor: 5.084

5.  Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig.

Authors:  Thomas R Lane; Christopher Massey; Jason E Comer; Alexander N Freiberg; Huanying Zhou; Julie Dyall; Michael R Holbrook; Manu Anantpadma; Robert A Davey; Peter B Madrid; Sean Ekins
Journal:  Antiviral Res       Date:  2020-07-16       Impact factor: 5.970

6.  Repurposing Quinacrine against Ebola Virus Infection In Vivo.

Authors:  Thomas R Lane; Jason E Comer; Alexander N Freiberg; Peter B Madrid; Sean Ekins
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

7.  Exploiting machine learning for end-to-end drug discovery and development.

Authors:  Sean Ekins; Ana C Puhl; Kimberley M Zorn; Thomas R Lane; Daniel P Russo; Jennifer J Klein; Anthony J Hickey; Alex M Clark
Journal:  Nat Mater       Date:  2019-04-18       Impact factor: 43.841

Review 8.  Turning omics data into therapeutic insights.

Authors:  Amanda Kedaigle; Ernest Fraenkel
Journal:  Curr Opin Pharmacol       Date:  2018-08-24       Impact factor: 5.547

Review 9.  Dissecting pharmacological effects of chloroquine in cancer treatment: interference with inflammatory signaling pathways.

Authors:  Lokman Varisli; Osman Cen; Spiros Vlahopoulos
Journal:  Immunology       Date:  2019-12-22       Impact factor: 7.397

Review 10.  Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection.

Authors:  Yuchen Xia; T Jake Liang
Journal:  Gastroenterology       Date:  2018-09-19       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.